期刊文献+

抗凝药物及其不良反应 被引量:8

Anticoagulant drugs and its adverse reactions
下载PDF
导出
摘要 抗凝药物被广泛用于血栓栓塞性疾病的预防与治疗,但不合理使用易致血栓复发以及皮肤黏膜出血、血尿甚至脑出血死亡,故安全、合理地使用抗凝药物十分重要。本文就各类抗凝药物及其不良反应情况作一简要介绍。 Anticoagulant drugs are widely used for the prevention and treatment of thromboembolic disease, but improper use may cause recurrent thrombosis and bleeding of skin mucous membrane, hematuria, and even the death of cerebral hemorrhage. The security and the rational use of anticoagulant drugs are very important. This article briefly introduces the anticoagulant drugs and their adverse reactions.
出处 《上海医药》 CAS 2013年第17期19-21,31,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 抗凝药物 合理用药 血栓 anticoagulant drugs rational administration thrombus
  • 相关文献

参考文献14

  • 1马培奇.口服抗血凝药物研究进展[J].上海医药,2011,32(9):462-464. 被引量:3
  • 2禹道春,李宏建,王介明.草药与华法林相互作用的研究[J].国外医学(中医中药分册),2003,25(6):344-345. 被引量:8
  • 3Lo ACT, Chan K, Yeung JRK, et al. Danggui (Angelica sinensis) affects the pharmacodynamics but not the pharmacokinetics of warfarin in rabbits[J]. Drug Metab Pharmacikenet, 1995,20(1): 55-66.
  • 4Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin[J]. Thromb Haemost, 2008, 99(5): 819-829.
  • 5Warkentin TE, Greinacher A, Koster A. Bivalirudin[J]. Thromb Haemost, 2008, 99(5): 830-839.
  • 6Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial[J]. Lancet, 2007, 370(9591): 949-956.
  • 7Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial[J]. J Thromb Haemost, 2007, 5(11): 2178-2185.
  • 8Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12): 1139-1151.
  • 9Clayton RA, Gaston P, Howie CR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement[J]. J Bone Joint Surg Br, 2010, 92(3): 468-468.
  • 10ROCKET AF study investigators. Rivaroxaban - once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study[J]. Am Heart J, 2010, 159(3): 340-347.

二级参考文献13

  • 1di Nisio M, Middeldorp S, Buller HR, et al. Direct thrombin inhibitors [ J ]. N Engl J Med, 2005, 353(10) : 1028-1040.
  • 2Stangier J, Rathgen K, Staehle H, et al. The phalmacokinetics, pharmacodynamics and tolerability of dabigatran ctexilate, a new oral direct thrombin inhibitor, in healthy rome subjects [J]. Br J Clin Pharmacol, 2007, 64(3): 292-303.
  • 3Ezekowitz MD, Connolly SJ, Parekh A, et al. Rationale and design of RE-LY : Randomized evaluation of long-term anticoagulation therapy, warfarin, compared with dabigatran [ J ]. Am Heart J, 2009, 157(5) : 805-810.
  • 4Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [ J ]. N Engl JMed, 2009, 361(12) : 1139-1151.
  • 5Perzbonl E, Slrassburger J, Wilmein A, et el. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 : An oral, direct factor Xa inhibitor [ J ]. J Thromh Haemost 2005, 3(3) : 514-521.
  • 6Mueck W, Eriksson BI, Bauer KA, et al. Pnpulation pharmacokinetics and pharmacodynamics of rivaroxaban--- an oral, direct Factor Xa inhibitor -in patients undergoing major orthopaedic surgery [ J J. Clin Pharmacokinet, 200,8, 47(3) : 203-216.
  • 7Ageno W. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery : The RECORD trials [ J ]. Expert Rev Cardiovasc Ther, 2009, 7(6) : 569-576.
  • 8Bayer Sehering Pharma AG. Stroke prevention in alrial fibrillation : ROCKET AF [ EB/OL ]. [2011-03-22]. http:// www.xareha.eom/en/elinieal-studies/stroke-prevention-inatrial- fi brillation/index.php?user=HCP.
  • 9Myers S P. Aust Prescr, 2002, 25:54-56.
  • 10Lam AY, Elmer GW, Mohutsky MA. Ann Pharmacother,2001, 35: 1199-1201.

共引文献9

同被引文献83

引证文献8

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部